HCW Biologics strengthens U.S. patent estate for HCW9302 alopecia areata
HCW Biologics says it has strengthened its U.S. patent estate for HCW9302, its lead clinical-stage immunotherapeutic for alopecia areata.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.